Jemperli is on a steep growth trajectory with GSK guiding to greater than £2 billion ($2.7 billion) peak monotherapy sales1
Quarterly Sales Performance $USD {MM)
US Quarterly Net Sales
EU Quarterly Net Sales
International Quarterly Net Sales
YoY Growth %
$313MM / £232MM in Q1 2026 sales2
>40% YoY quarterly growth rate
Annual Sales Performance $USD {MM)
US Annual Net Sales
EU Annual Net Sales
International Annual Net Sales
YoY Growth %
$1.128MM /£861MM in FY 2025 sales2
89% YoY growth rate
$1.221MM /£919MM in LTM sales2
Far greater than
$2.7 billion peak sales1
guidance from GSK
Implies > $390 million
in annualized Jemperli royalties payable to Anaptys — as early as 20293
1. CEO Emma Walmsley, 2025 JP Morgan CEO Series fireside chat, 9/11/2025, “there’s no change to our peak year sales overall ambition for Jemperli, that’s for sure, which is far more than £2 billion.”; 2. GSK Q1 2026 earnings presentation, US dollar conversion Int.: International; 3. Anaptys expectation